A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Part of paid clinical trials in Hackensack, New Jersey.

Sponsor
Bristol-Myers Squibb
Study ID
NCT04112498
Phase
PHASE1
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • relatlimab — DRUG
    Specified dose on Specified days
  • nivolumab — DRUG
    Specified dose on Specified days
  • rHuPH20 — DRUG
    Specified dose on Specified days

Study Details

This study will characterize the movement of drugs within the body, evaluate safety and determine to which extent the body can process relatlimab in combination with nivolumab in subjects with certain advanced tumors

Key Dates

Start date
Oct 1, 2019
Status verified
Apr 2023
Primary completion
Feb 27, 2023
Completion
Feb 27, 2023

Study Design

Enrollment
24 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: nivolumab + relatlimab + rHuPH20

Primary Outcome Measure

maximum observed serum concentration (Cmax) [ Time Frame: approximately 60 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Local Institution - 0001HackensackNew Jersey07601-

Find similar trials in Hackensack, NJ

By research site
Local Institution - 0001· Hackensack, NJ

Related Studies